HPS Pharmacies wish to advise that Pfizer is experiencing a supply interruption for Heparinised Saline as follows:
Heparinised Saline
Heparin sodium 50 IU/5mL
ARTG 66684
This supply interruption is expected to resolve by the end of January 2025.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered for use in the United Kingdom and all packaging is in English. It is identical to the Australian registered product for active ingredient, strength, and excipients. However, there are some presentation differences, as shown in the table below.
| Heparinised saline (Pfizer) | Heparin sodium flushing solution (Wockhardt) | |
| Product type | Australian registered | S19A |
| Labelled as | Heparinised saline | Heparin sodium flushing solution |
| Pack size | 50 ampoules | 10 ampoules |
| Presentation | LDPE ampoules | Glass ampoules |
The S19A alternative (Heparin sodium flushing solution [Wockhardt]) is pictured below. The Summary of Product Characteristics can be accessed here.
 |
 |
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates